| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.26 | 1e-05 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.14 | 2e-05 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.19 | 0.0001 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.0002 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.099 | 0.001 |
| mRNA | semagacestat | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.1 | 0.001 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.19 | 0.002 |
| mRNA | Mitomycin-C | CTRPv2 | pan-cancer | AAC | -0.1 | 0.002 |